山西建投
SHANXI CIG

華控康泰集團有限公司
Kontafarma China Holdings Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1312)

PROFIT WARNING

This announcement is made by Kontafarma China Holdings Limited (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors (the "**Board**") of the Company wishes to inform the shareholders of the Company (the "**Shareholders**") and potential investors that, based on a preliminary assessment of the latest unaudited consolidated management accounts of the Group for the six months ended 30 June 2026 (the "**Period**") and the latest information available to the Board, it is expected that the Group will record a consolidated net loss in the range of approximately HK$67.2 million to HK$100.7 million for the Period (the consolidated net loss for the corresponding six months ended 30 June 2025 (the "**1H 2025**") was approximately HK$321.4 million).

The consolidated net loss of the Group for the Period was mainly attributable to the impairment losses expected to be in the range of approximately HK$51.0 million to HK$63.1 million in respect of the fitness business of the Group in Singapore, in particular (i) an impairment loss on property, plant and equipment in the range of approximately HK$1.6 million to HK$2.4 million; (ii) an impairment loss on right-of-use assets in the range of approximately HK$9.7 million to HK$14.6 million; (iii) an impairment loss on intangible assets in the range of approximately HK$12.8 million to HK$19.2 million; and (iv) an impairment loss on goodwill related to the fitness business in Singapore of approximately HK$26.9 million.

The consolidated net loss of the Group for the Period is expected to decrease when compared to that of the 1H 2025 mainly because the impairment losses of approximately HK$373.6 million recorded for the fitness business of the Group in Taiwan and Singapore in the 1H 2025 was substantially higher than the impairment losses expected to be in the range of approximately HK$51.0 million to HK$63.1 million in respect of the fitness business of the Group in Singapore for the Period. Having said that, following the cessation of operation of franchise fitness business of the Group in Taiwan since 1 October 2025 as disclosed in the inside information announcement of the Company dated 30 September 2025, the fitness business of the Group in Singapore has been increasingly challenging. As disclosed in the annual report of the Company for the financial year ended 31 December 2025 published on 23 April 2026, the fitness business of the Group in Singapore faces multiple challenges, including but not limited to the increasingly fierce market competition, and rising costs in attracting customers. The Group owns its fitness business in Singapore through its indirect non-wholly owned subsidiary, namely TFKT True Holdings (together with its subsidiaries incorporated in Singapore for operation of the fitness business of the Group, the "**TFKT Group**"). In order to sustain the business operation of the TFKT Group, the Company has been providing cash funding and financial support to the TFKT Group hoping to ease its significant liquidity pressure. The Group is also making best endeavours to control costs and optimise operational efficiency of its fitness business in Singapore amid the fiercely challenging market. The Group will continue to evaluate from time to time its business strategy for the fitness business in Singapore and, where necessary, make appropriate adjustments or measures for the interest of the Company and its Shareholders as a whole.

INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2026 WILL BE PUBLISHED BY THE END OF AUGUST 2026

The information in this announcement is based on a preliminary assessment by the management of the Company according to the unaudited consolidated management accounts of the Group for the Period. Such information has not been finalised, audited or reviewed by the Company's independent auditor, and has not been confirmed by the audit committee of the Company. Shareholders and potential investors are advised to refer to the details in the results announcement of the Company for the Period, which is expected to be published on or around 28 August 2026. There may be changes or adjustments following review of the unaudited management accounts by the independent auditor of the Company.

Shareholders and potential investors are advised to exercise caution when dealing in shares or other securities of the Company.

By order of the Board of
Kontafarma China Holdings Limited
Wang Limin
Chairman

Hong Kong, 17 August 2026

As at the date of this announcement, the Board comprises four executive Directors, namely Mr. Wang Limin (Chairman), Mr. Li Qingshan (President), Mr. Ge Shouwen (Vice President), and Ms. Guo Zixiu (Financial Controller); and three independent non-executive Directors, namely Dr. Tang Lai Wah, Dr. Ho Ho Ming and Mr. Yao Xiaomin.